D-Beta-Hydroxybutyrate.

Medium-chain fatty acids bypass the carnitine shuttle, reach the liver by the portal route and are oxidised to acetyl-CoA fast enough that a share is diverted into ketone synthesis. That raises endogenous D-beta-hydroxybutyrate on top of what an exogenous ketone supplies. The two routes are complementary: one is absorbed as the ketone itself, the other is converted in the liver.

Caprylic acid, the eight-carbon fraction, is the most ketogenic of the medium-chain fatty acids because it is oxidised most readily. Pairing it with exogenous D-beta-hydroxybutyrate produces both an immediate rise from absorption and a slower rise from liver conversion. Gastrointestinal tolerance sets the practical ceiling on the C8 side.

Caprylic acid enters mitochondria without carnitine transport and generates acetyl-CoA that feeds HMG-CoA synthase in liver mitochondria. The output is acetoacetate and then D-beta-hydroxybutyrate. This is the standard conversion route behind ketogenic fat blends.

Beta-hydroxybutyrate is an acid, so supplement forms are usually neutralised with sodium, potassium, calcium or magnesium. A gram-scale ketone salt dose therefore carries a meaningful mineral load that has to be counted in the day's total. Adding a separate electrolyte product on top compounds that arithmetic.

Sodium is the most common counter-ion in ketone salts because it gives the most soluble and least bitter product. Multi-gram servings can contribute a substantial fraction of a day's sodium. Anyone tracking sodium needs the salt form on the label, not just the ketone figure.

Potassium is used alongside sodium to lower the sodium share of a ketone salt. Because potassium load matters to anyone with reduced kidney clearance, the counter-ion split is a formulation decision with consequences beyond taste. State the milligrams rather than only the ketone total.

Magnesium beta-hydroxybutyrate contributes magnesium in the same serving, and magnesium is separately the obligate counter-ion for ATP in every kinase reaction that spends it. So the mineral is both a formulation choice and a cofactor for the energy pathways the ketone feeds. Magnesium from a ketone salt counts toward the daily intake.

Calcium beta-hydroxybutyrate is less soluble and less salty-tasting than the sodium form, which is why blends use it to shift the mineral profile. The calcium arriving with a multi-gram serving is real and should be added to total intake. Calcium in the same serving can also compete with other minerals for absorption.

Caffeine raises circulating free fatty acids through adenosine receptor blockade and higher catecholamine tone, which increases the substrate available for hepatic ketone synthesis. Exogenous D-beta-hydroxybutyrate meanwhile arrives already made. The pairing is standard in performance blends; the combined effect on ketone levels has not been well quantified.

Creatine buffers ATP over seconds through the phosphocreatine system, while beta-hydroxybutyrate is an oxidative fuel delivered over tens of minutes. They serve different time domains of energy supply and do not compete for the same transporters. The pairing is rational on physiology; no combination trial establishes an additive performance result.

Long-chain fatty acids require carnitine palmitoyltransferase to enter mitochondria, and that flux is what supplies the acetyl-CoA for hepatic ketogenesis. Carnitine adequacy therefore sits upstream of endogenous ketone production. It does not affect the handling of ketone that is swallowed already formed.

Leucine is the one strictly ketogenic amino acid: its carbon skeleton is degraded to acetoacetate and acetyl-CoA rather than to glucose precursors. That places a modest amount of ketone body production downstream of leucine intake. The contribution is small next to a gram-scale exogenous dose.

Beta-hydroxybutyrate and butyrate are both short-chain carboxylic acids that bind the hydroxycarboxylic acid receptor HCAR2 on adipocytes and immune cells, and both act as histone deacetylase inhibitors at millimolar concentrations. Butyrate is also oxidised by colonocytes to acetyl-CoA. The overlap in receptor and epigenetic action is well described in the literature; the clinical consequence of combining them is not.

Beta-hydroxybutyrate dehydrogenase converts BHB to acetoacetate using NAD as the electron acceptor, so ketone oxidation shifts the mitochondrial NADH to NAD ratio. NAD precursors support the size of that pool. The link is biochemical; no trial has tested whether an NAD precursor changes ketone utilisation in people.

The first step of ketone body oxidation is NAD dependent, and the sirtuins that respond to a more reduced mitochondrial state also consume NAD. NMN feeds the same nucleotide pool. This is a cofactor relationship rather than a demonstrated performance combination.

The reducing equivalents generated when beta-hydroxybutyrate is oxidised are passed through complexes I and II to ubiquinone before reaching complex III. Coenzyme Q10 is that carrier. Adequate ubiquinone is a requirement of the pathway, which is different from saying supplemental Q10 raises ketone utilisation.

Thiamine pyrophosphate is the cofactor for pyruvate dehydrogenase and for alpha-ketoglutarate dehydrogenase, the two gates that decide whether carbon enters the TCA cycle or backs up into ketone production. Metabolomic work in dairy cows links thiamine status to how ketone bodies are handled, which is an animal finding and not human evidence. The cofactor relationship itself is settled biochemistry.

Acyl-CoA dehydrogenases are flavoproteins, so every round of fatty acid beta-oxidation that supplies acetyl-CoA for ketogenesis needs FAD derived from riboflavin. Riboflavin adequacy therefore underpins endogenous ketone production. It has no bearing on ketone that is ingested directly.

Taurine is a cell osmolyte and conjugates bile acids, which matters when a high fat intake accompanies ketone use. It is commonly included in ketone drink mixes for tolerance and taste reasons. No study has examined taurine with exogenous D-beta-hydroxybutyrate.

Whey provokes a brisk insulin release, and insulin is the strongest physiological brake on hepatic ketone production and on adipose lipolysis. Taking whey around a ketone dose therefore suppresses the endogenous contribution even though it does not stop absorption of the ingested ketone. Timing the two apart is the usual response when a nutritional ketosis state is the goal.

Glutamine is a significant gluconeogenic substrate, particularly in the intestine and kidney, so a large dose supplies carbon that raises glucose availability. Higher glucose availability lowers the drive to ketone production. The direction follows from established metabolism; the size of the effect at supplement doses has not been measured.

Beta-hydroxybutyrate is an organic acid, and multi-gram doses given as a free acid or ester impose a measurable acid load that the bicarbonate buffer absorbs. Bicarbonate supplementation is separately used for its buffering effect during high-intensity work. Both change the same buffer system, so the two should be counted together rather than assumed independent.

Long-chain omega-3 fatty acids are oxidised through the same mitochondrial and peroxisomal machinery that supplies acetyl-CoA for ketone synthesis, and they influence PPAR-alpha signalling, which regulates ketogenic gene expression. This makes a background contribution rather than an acute one. Nothing has tested the combination for a ketone effect.